viral protease inhibitor
A viral protease inhibitor is a drug that blocks the molecular scissors a virus needs to finish assembling itself. Many viruses first make their proteins as one long chain that must be snipped into working pieces; the viral protease does the snipping, and without it the new viruses come out defective and non-infectious.
Chemically, these inhibitors are usually designed to mimic the part of the viral protein the protease normally cuts, but with an uncleavable bond, so the enzyme grips the drug and gets stuck instead of doing its job. Designers shape the molecule to fit the unique walls of the viral protease's active site, which differs from our own proteases enough to give selectivity.
Viral protease inhibitors transformed HIV care in the 1990s and reappeared powerfully against hepatitis C and COVID-19. Their honest challenges are familiar: viruses mutate the protease to weaken drug binding, and because the same enzyme cuts several sites, achieving high potency without off-target effects on human proteases takes careful design — which is also why one COVID drug is co-dosed with a CYP-blocker to keep blood levels high enough.
Nirmatrelvir blocks the SARS-CoV-2 main protease and is given with ritonavir, which slows its breakdown by CYP3A4 so effective levels last.
A booster drug keeps the protease inhibitor at working concentrations.
Designing these drugs is a classic case of structure-based drug design: crystal structures of the viral protease guided molecules that snugly fill its active site.